Patent US5138045A successfully refreshed from Google Patents.
US5138045A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polyamine conjugated oligonucleotides
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 1990-07-27
•
Granted: 1992-08-11
•
Expires: 2010-07-27
Abstract
Abstract Oligonucleotide analogs are provided having improved cellular uptake and improved nuclease resistance. Modification of oligonucleotides through the attachment of nitrogenous moieties, especially polyamines, hydrazines and the like to nucleosidic portions of the analogs is disclosed. Oligonucleotides targeted at the tat region of HIV comprise certain preferred embodiments.
Inventors
- 👤 Philip D. Cook
- 👤 Charles J. Guinosso
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 07:06
CPC Classifications
C; C07; C07D; C07D405/00; C07D405/02; C07D405/04; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/54; A61K47/549; A61K47/56; A61K47/59; A61P; A61P31/00; A61P31/12; C07D405/14; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/18; C07F7/1804; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H19/10; C07H19/16; C07H21/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
23 words
An oligonucleotide analog having at least one nucleoside modified by direct attachment of a polyamine at the 5' site of its sugar moiety.
Claim 2
Dependent Claim
23 words
An oligonucleotide analog having at least one nucleoside modified by direct attachment of a polyamine at the 5' site of its sugar moiety.
Claim 3
Dependent Claim
22 words
The oligonucleotide analog of claim 1 wherein the oligonucleotide analog ranges in length from about 5 to about 50 nucleotide base unit.
Claim 4
Dependent Claim
11 words
The oligonucleotide analog of claim 1 wherein said nucleoside is thymidine.
Claim 5
Dependent Claim
20 words
The oligonucleotide analog of claim 1 wherein said polyamine is a primary amine, a hydrazine, a semicarbazide, or a thiosemicarbazide.
Claim 6
Dependent Claim
16 words
The oligonucleotide analog of claim 1 specifically hybridizable with the tat region of an HIV genome.
Claim 7
Dependent Claim
18 words
The oligonucleotide analog of claim 5 wherein said selected sequence has a thymidine at its 5' terminal end.
Claim 8
Dependent Claim
16 words
The oligonucleotide analog of claim 1 specifically hybridizable with a selected portion of a herpes genome.
Claim 9
Dependent Claim
15 words
The oligonucleotide of claim 1 specifically hybridizable with a selected portion of a papilloma genome.
Claim 10
Dependent Claim
26 words
the oligonucleotide analog of claim 1 wherein said polyamine has the structure: H.sub.2 N(CH.sub.2).sub.n NH(CH.sub.2).sub.n NH(CH.sub.2).sub.n NH-- wherein n is an integer between 2 and 6.
Claim 11
Dependent Claim
10 words
The oligonucleotide analog of claim 9 wherein n is 4.
Claim 12
Dependent Claim
12 words
The oligonucleotide analog of claim 1 comprising at least one phosphorothioate group.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-08-11 | 1996-02-10 | 1996-08-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-08-11 | 2000-02-10 | 2000-08-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-08-11 | 2004-02-10 | 2004-08-11 | $7700.00 | Window Closed / Lapsed |